The consensus molecular subtypes of colorectal cancer as a predictive factor for chemotherapies against metastatic colorectal cancer.
The consensus molecular subtypes of colorectal cancer as a predictive factor for chemotherapies against metastatic colorectal cancer.
复制标题
DOI：
10.1200/jco.2018.36.4_suppl.736
复制
发表时间：
2018-02
影响因子：
45.3
通讯作者：
A. Okita;Shin Takahashi;K. Ouchi;M. Inoue;Y. Yamada;C. Ishioka
中科院分区：
文献类型：
--
作者：
A. Okita;Shin Takahashi;K. Ouchi;M. Inoue;Y. Yamada;C. Ishioka
背景：由于转移性结直肠癌化疗选择的多样性，需要能够预测化疗疗效的生物标志物才能达到最佳治疗效果。在这项研究中，我们分析了几种化疗方法的治疗结果与共识分子亚型(CMS)的关系，CMS是从大规模的结直肠癌综合基因表达分析中发展出来的(Guinney J等人)。NAT Med 21：1350-6,2015)。方法：利用原发灶基因芯片数据和R软件中的“CMS分类器”软件包，将193例既往治疗的mCRC患者分为CMS1~CMS4型4个亚型。并对各亚型与治疗结果的关系进行了回顾性分析。结果：193例患者分为CMS1 21例，CMS2 53例，CMS3 69例，CMS4 50例。各亚型的KRAS、BRAF基因突变状态、DNA甲基化状态等分子特征与临床表现一致。
736Background: Since treatment options of chemotherapy for metastatic colorectal cancer (mCRC) have been diversified, biomarkers which could predict efficacy of chemotherapies are needed for optimal treatment. In this study, we analyzed the association of the treatment outcomes by several chemotherapies and the consensus molecular subtypes (CMS), which was developed from large-scale comprehensive gene expression analysis of colorectal cancer (Guinney J et al. Nat Med 21:1350-6, 2015). Methods: A total of 193 patients with previously treated mCRC were classified in 4 subtypes, CMS1 to CMS4 by using the microarrays data of primary tumors and the “CMS classifier” package for the R software. Then the association between the subtypes and the treatment outcomes was analyzed retrospectively. Results: The193 cases were classified into 21 CMS1, 53 CMS2, 69 CMS3 and 50 CMS4. The molecular characteristics of each subtype such as mutation status of KRAS and BRAF genes, and DNA methylation status were consistent with ...